Status:
COMPLETED
Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this observational study is to evaluate the efficacy on blood glucose control while using NovoMix® 30 FlexPen® under normal clinical practice conditions in ...
Eligibility Criteria
Inclusion
- Any patient with type 1 and type 2 diabetes who are treated with NovoMix® 30
- Patient who signed on informed consent form
Exclusion
- Patients who are unlikely to comply with protocol requirements, e.g., uncooperative attitude, inability to return for the final visit
- Patients who were previously enrolled in this study
- Patients with a hypersensitivity to NovoMix® 30 or to any of the excipients
- Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
1068 Patients enrolled
Trial Details
Trial ID
NCT00737776
Start Date
May 1 2008
End Date
January 1 2010
Last Update
October 31 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Seoul, South Korea, 137-920